Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
Bellus Health Inc
ClinicalTrials.gov Identifier:
NCT00035334
First received: May 2, 2002
Last updated: February 13, 2006
Last verified: February 2006
  Purpose

The main objective of this study is to evaluate the safety and efficacy of NC-503 compared to placebo in patients with secondary (AA) amyloidosis using a composite assessment of clinical improvement/worsening of both renal and gastrointestinal functions.


Condition Intervention Phase
Secondary (AA) Amyloidosis
Rheumatoid Arthritis
Nephrotic Syndrome
Familial Mediterranean Syndrome
Kidney Diseases
Gastrointestinal Diseases
Drug: NC-503 (Anti-amyloidotic (AA) Agent)
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Phase II/III Study of the Safety and Efficacy of NC-503 in Patients Suffering From Secondary (AA) Amyloidosis

Resource links provided by NLM:


Further study details as provided by Bellus Health Inc:

Estimated Enrollment: 150
Study Start Date: October 2001
Estimated Study Completion Date: December 2004
Detailed Description:

AA amyloidosis is associated with chronic inflammatory conditions (rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease), chronic infection (tuberculosis, osteomyelitis), and Familial Mediterranean Fever. Rheumatoid arthritis is the major cause of AA amyloidosis in Western Europe and North America. The most common clinical feature of AA amyloidosis is renal dysfunction manifested as nephrotic-range proteinuria or renal insufficiency at the time of diagnosis. End-stage renal failure is the cause of death in 40-60% of cases. Gastrointestinal involvement is also frequent and is usually manifested as chronic diarrhea, body weight loss and malabsorption. Enlargement of the liver and spleen may also occur in some patients. The median survival time from diagnosis varies from 2 to 8 years depending on the stage of the disease at time of diagnosis. The goal of the current therapy in AA amyloidosis is the control of the associated disease. However, the current approaches for the treatment of AA amyloidosis are unspecific, toxic, invasive, and not sufficiently effective in many cases. NC-503 was specifically designed to compete with the naturally occurring sulfated GAGs for the binding to amyloidogenic precursor proteins, and to inhibit amyloid deposition into tissues. The proposed therapy with NC-503 is based on the prevention of the amyloid fibril formation. The objective of this clinical phase II/III study is to determine the efficacy and safety of NC-503 compared to a placebo in patients suffering from secondary (AA) amyloidosis by the assessment of clinical improvement/ worsening of both renal and gastrointestinal functions.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

PROTOCOL INCLUSION CRITERIA

  • Patients must be 18 years of age or older.
  • Males and females. If women of childbearing potential (i.e., not surgically sterilized or post-menopausal greater than one year) the patient must be using effective birth control.
  • Diagnosis of AA amyloidosis demonstrated by positive biopsy (Congo red staining) and immunohistochemistry or immunoelectron microscopy at screening visit. Tissue from previous biopsy can be used for confirmation of diagnosis, if available.
  • Persistent proteinuria defined as urinary protein excretion ? 1g/24h in two distinct 24-h urine collections at least 1 week apart within 3 months prior to study entry (baseline, Month 0 visit) without evidence of urinary tract infection or overt heart failure (NYHA class III or more); OR creatinine clearance ? 60 mL/min in two distinct measures at least 1 week apart within 3 months prior to study entry (baseline, Month 0 visit).
  • Creatinine clearance ? 20 mL/min AND serum creatinine ? 3 mg/dl within 3 months prior to study entry (baseline, Month 0 visit).
  • Written informed consent.

PROTOCOL EXCLUSION CRITERIA

  • Evidence or suspicion of renal or renovascular diseases other than renal AA amyloidosis.
  • Presence of diabetes mellitus (Type I and II).
  • Evidence of a cause of potentially reversible reduced renal function, such as accelerated hypertension or drug nephrotoxicity.
  • AST, ALT, or ALP > 5 times the upper limit of normal, or total bilirubin 50% above upper limits of normal.
  • Presence of any other clinically significant diseases that could interfere with the interpretation of study results or compromise patient safety or any conditions that could reduce life expectancy to less than two years.
  • Use of an investigational drug within thirty days prior to the screening visit.
  • Active alcohol and/or drug abuse.
  • Initiation of or any changes in ACE inhibitor therapy within 3 months prior to the screening visit.
  • Initiation of or any changes in cytotoxic agents/colchicine therapy within 3 months prior to the screening visit.
  • Inability to provide legal consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00035334

  Show 26 Study Locations
Sponsors and Collaborators
Bellus Health Inc
  More Information

Publications:
Safety, Tolerability and Pharmacokinetic Profile of FibrillexTM (Anti-AA Amyloid Agent) in Healthy and Renal Impaired Subjects. Garceau D., Gurbindo C., Laurin J. Neurochem Inc. Reference: Proceedings from the IXth International Symposium on Amyloidosis , 2001 (Budapest, Hungary)

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00035334     History of Changes
Obsolete Identifiers: NCT00017667
Other Study ID Numbers: CL-503004
Study First Received: May 2, 2002
Last Updated: February 13, 2006
Health Authority: United States: Food and Drug Administration

Keywords provided by Bellus Health Inc:
Familial Mediterranean Fever
Amyloidosis
Secondary (AA) Amyloidosis
Nephrotic Syndrome

Additional relevant MeSH terms:
Amyloidosis
Arthritis, Rheumatoid
Digestive System Diseases
Gastrointestinal Diseases
Kidney Diseases
Neoplasm Metastasis
Nephrotic Syndrome
Syndrome
Arthritis
Autoimmune Diseases
Connective Tissue Diseases
Disease
Immune System Diseases
Joint Diseases
Metabolic Diseases
Musculoskeletal Diseases
Neoplasms
Neoplastic Processes
Nephrosis
Pathologic Processes
Proteostasis Deficiencies
Rheumatic Diseases
Urologic Diseases

ClinicalTrials.gov processed this record on November 24, 2014